← Eichor
Study identifier: NCT03866382 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Condition: Bladder Adenocarcinoma · Bladder Clear Cell Adenocarcinoma · Bladder Mixed Adenocarcinoma  ·  Sponsor: National Cancer Institute (NCI)

PhasePhase 2
Planned participants314
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (582)

University of Alabama at Birmingham Cancer CenterBirmingham, Alabama, United StatesActive Not Recruiting
Anchorage Associates in Radiation MedicineAnchorage, Alaska, United StatesSuspended
Anchorage Radiation Therapy CenterAnchorage, Alaska, United StatesSuspended
Alaska Breast Care and Surgery LLCAnchorage, Alaska, United StatesSuspended
Alaska Oncology and Hematology LLCAnchorage, Alaska, United StatesSuspended
Alaska Women's Cancer CareAnchorage, Alaska, United StatesSuspended
Anchorage Oncology CentreAnchorage, Alaska, United StatesSuspended
Katmai Oncology GroupAnchorage, Alaska, United StatesSuspended
Providence Alaska Medical CenterAnchorage, Alaska, United StatesSuspended
Kingman Regional Medical CenterKingman, Arizona, United StatesSuspended
Cancer Center at Saint Joseph'sPhoenix, Arizona, United StatesActive Not Recruiting
Mayo Clinic Hospital in ArizonaPhoenix, Arizona, United StatesRecruiting

+ 570 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03866382